NVision has secured $55 million in Series B funding to drive the development of its quantum healthcare platform, expanding its focus from quantum sensing to quantum computing for healthcare and drug development1. The company aims to integrate quantum computing for drug design with its POLARIS quantum-enhanced MRI platform, which is designed to validate therapies. NVision's approach involves the use of a photonic quantum computing platform, leveraging organic molecule qubits integrated onto photonic chips. This innovative technology has the potential to revolutionize the field of healthcare by enabling faster and more accurate drug development and therapy validation. The significant funding injection will likely accelerate the development and deployment of NVision's quantum healthcare solutions, which could have a profound impact on the industry. This matters to practitioners and informed readers because it signals a major investment in the potential of quantum computing to transform healthcare and drug development.